STXS Stereotaxis

Stereotaxis to Report Third Quarter 2020 Financial Results on November 9, 2020

Stereotaxis to Report Third Quarter 2020 Financial Results on November 9, 2020

ST. LOUIS, Oct. 26, 2020 (GLOBE NEWSWIRE) -- (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2020 third quarter on Monday, November 9, 2020 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10:00 a.m. Eastern Time that day to discuss the Company’s results and corporate developments.

What:Stereotaxis third quarter financial results conference call
  
When:Monday, November 9, at 10:00 a.m. Eastern Time (7:00 a.m. PT)
  
Dial In Number:To access the live call, dial 800-437-2398 (US and Canada) or 856-344-9206 (International) and give the participant pass code 9232669.
  
Webcast: To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at
  
Call Replay:A phone replay of the call will be available for one week beginning approximately two hours following the end of the call through November 30, 2020. To request access for a replay of the conference call, please .

About Stereotaxis

is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit .

Company Contacts:

David L. Fischel

Chairman and Chief Executive Officer

Kimberly Peery

Chief Financial Officer

314-678-6100

EN
26/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Stereotaxis

 PRESS RELEASE

First US Commercial Robotic HD Mapping Procedures Successfully Complet...

First US Commercial Robotic HD Mapping Procedures Successfully Completed with MAGiC Sweep Catheter ST. LOUIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the successful completion of the world’s first procedures using MAGiC Sweep™, the first and only robotically-navigated high-density electrophysiology (EP) mapping catheter. The procedures were performed by Dr. Raffaele Corbisiero and Dr. Pedram Kazemian at Deborah Heart and Lung Center in Browns Mills, New J...

 PRESS RELEASE

Stereotaxis to Present at Upcoming Investor Conferences

Stereotaxis to Present at Upcoming Investor Conferences ST. LOUIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will present at two investor conferences in New York City in September. Mr. Fischel will present an overview of Stereotaxis business on Wednesday, September 10th, 2025, at 8:00 am EDT and will be available that same day for one-on-one meetings. Mr. Fischel will be available for one-on-one meetings on T...

 PRESS RELEASE

Stereotaxis Technology to be Featured at Heart Rhythm Society’s HRX 20...

Stereotaxis Technology to be Featured at Heart Rhythm Society’s HRX 2025 ST. LOUIS, Aug. 28, 2025 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced its technology will be featured during the upcoming HRX digital health conference taking place September 4-6, 2025, in Atlanta, Georgia. HRX, an initiative pioneered by the Heart Rhythm Society, is focused on exploring digital technologies that advance the frontiers of cardiovascular medicine. Stereotaxis CEO, David Fischel, will participate in...

 PRESS RELEASE

Stereotaxis Reports 2025 Second Quarter Financial Results

Stereotaxis Reports 2025 Second Quarter Financial Results ST. LOUIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2025. “We are pleased with our commercial results in the quarter. Sequential and year-over-year growth in both recurring and system revenue reflects the early positive impact of our innovations on commercial adoption,” said David Fischel, Chairman and CEO. “This is an exciting milestone rich year with bro...

 PRESS RELEASE

Stereotaxis Receives U.S. FDA Clearance for MAGiC Sweep Catheter

Stereotaxis Receives U.S. FDA Clearance for MAGiC Sweep Catheter ST. LOUIS, July 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its groundbreaking MAGiC Sweep™ catheter. MAGiC Sweep is the world’s first robotically navigated high-density electrophysiology (EP) mapping catheter, representing a significant advancement in the technology available to diagnose and treat complex arrhythmia pat...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch